Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights

<p>– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023– Completed $25.5 Million Private Placement– Restructured and reduced secured debt with Horizon Technology Finance Corporation CAMBRIDGE, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq: EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology company developing […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/evelo-biosciences-announces-second-quarter-financial-results-and-recent-business-highlights/">Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>